Automated immunoassay platforms for enhancing AAV analytics

Adeno-associated viruses (AAVs) are the leaders in therapeutic gene delivery, distinguished by their remarkable capacity to efficiently infect a diverse range of cell types. Despite their successes, the industry still grapples with hurdles in producing and characterizing high-quality AAVs at a clinical scale with optimal efficiency. To achieve groundbreaking advancements in therapeutic interventions, advancements in AAV analytical tools are needed. The confluence of PROGEN’s 40-year legacy of reagent expertise with Bio-Techne's automated analytical solutions is a catalyst for redefining the future of gene therapy.

This webinar unveils the transformative power of automation in analytical AAV tools, introducing an era of unparalleled precision, reproducibility, and consistency.

• Discover the significance of top-tier AAV antibody and protein reagents
• Learn how to achieve fast and reproducible AAV titer using validated assay cartridges on Ella, an automated ELISA platform
• See how Simple Western pairs molecular weight information with analytical grade immunoassay quantitation, providing an ideal tool for protein expression potency assays and other CQAs
• Understand how a multi-attribute analytical tool such as Maurice can assist in unraveling CQAs from development through QC release

Lisa Mutz

Product Manager at PROGEN

Lisa Mutz studied biology with a focus on molecular and cellular biology at the University in Heidelberg, Germany. In 2021, she finished her Master studies with the analysis of protein-protein interactions of the nuclearpore proteins Nup50/Nup53 by Bio-ID. Subsequently, after her thesis, Lisa started her role as a Product Manager at PROGEN in Heidelberg, Germany, where she initially started overseeing the non-AAV life science portfolio. In 2022, Lisa took over responsibility for the AAV portfolio, which represents PROGEN´s main focus area within the field of gene therapy.

Chris Heger

Director of Applications Science, Analytical Solutions Division at Bio-techne

Dr. Chris Heger serves as the Director of Applications Science for Bio-Techne. He received his Ph.D. in Pharmacology from Cornell University and completed his post-doctoral training at the NCI. He joined Bio-Techne in 2012 and currently leads Applications Science group chartered with applications and content development, fostering collaborations, and providing custom analytical solutions. He’s a member of Bio-Techne’s Science and Technology Council and serves as technical expert for Bio-Techne Corporate Development.

Watch now

SPEAKERS

Lisa Mutz

Product Manager at PROGEN

Chris Heger

Director of Applications Science, Analytical Solutions Division at Bio-techne

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 50

Days

Register

Specifications don’t tell the whole story: how to choose GMP process and QC equipment

M Kay Bates, W Marin, K Whitlatch

18 June

in 41

Days

Register

Revolutionary innovations are underway to industrialize cell and gene therapies

Mark Santos

13 June

in 36

Days

Register

Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products

Ryan Massopust

11 June

in 34

Days

Register

Mastering the journey from initial method transfer to successful lot release for cell & gene therapies

A Chang, H Malicki, J Cheung et al.

6 June

in 29

Days

Register